Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network

Zexian Zeng,Jingxin Fu,Carrie Cibulskis,Aashna Jhaveri,Curtis Gumbs,Biswajit Das,Beatriz Sanchez-Espiridion,Sylvie Janssens,Len Taing,Jin Wang,James Lindsay,Tomas Vilimas,Jianhua Zhang,Collin Tokheim,Avinash Sahu,Peng Jiang,Chunhua Yan,Dzifa Yawa Duose,Ethan Cerami,Li Chen,David Cohen,Qingrong Chen,Rebecca Enos,Xin Huang,Jack J. Lee,Yang Liu,Donna S. Neuberg,Cu Nguyen,Candace Patterson,Sharmistha Sarkar,Sachet Shukla,Ming Tang,Junko Tsuji,Mohamed Uduman,Xiaoman Wang,Jason L. Weirather,Jijun Yu,Joyce Yu,Jianjun Zhang,Jiexin Zhang,Daoud Meerzaman,Magdalena Thurin,Andrew Futreal,Chris Karlovich,Stacey B. Gabriel,Ignacio Ivan Wistuba,X. Shirley Liu,Catherine J. Wu

DOI: https://doi.org/10.1158/1078-0432.ccr-20-3251

IF: 13.801

2020-12-15

Clinical Cancer Research

Abstract:Abstract Purpose: Whole-exome (WES) and RNA sequencing (RNA-seq) are key components of cancer immunogenomic analyses. To evaluate the consistency of tumor WES and RNA-seq profiling platforms across different centers, the Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Cancer Immunologic Data Commons (CIDC) conducted a systematic harmonization study. Experimental Design: DNA and RNA were centrally extracted from fresh frozen and formalin-fixed paraffin-embedded non–small cell lung carcinoma tumors and distributed to three centers for WES and RNA-seq profiling. In addition, two 10-plex HapMap cell line pools with known mutations were used to evaluate the accuracy of the WES platforms. Results: The WES platforms achieved high precision (> 0.98) and recall (> 0.87) on the HapMap pools when evaluated on loci using > 50× common coverage. Nonsynonymous mutations clustered by tumor sample, achieving an index of specific agreement above 0.67 among replicates, centers, and sample processing. A DV200 > 24% for RNA, as a putative presequencing RNA quality control (QC) metric, was found to be a reliable threshold for generating consistent expression readouts in RNA-seq and NanoString data. MedTIN > 30 was likewise assessed as a reliable RNA-seq QC metric, above which samples from the same tumor across replicates, centers, and sample processing runs could be robustly clustered and HLA typing, immune infiltration, and immune repertoire inference could be performed. Conclusions: The CIMAC collaborating laboratory platforms effectively generated consistent WES and RNA-seq data and enable robust cross-trial comparisons and meta-analyses of highly complex immuno-oncology biomarker data across the NCI CIMAC-CIDC Network.

oncology